摘要
目的了解缺血性卒中二级预防药物治疗的依从性及影响抗血小板药物依从性的因素,为规范缺血性卒中二级预防提供依据。方法 2007年8月～12月期间连续收入北京21家医院神经内科病房的缺血性卒中及TIA患者,对其中复发性卒中541例患者进行回顾性分析。结果 541例复发性卒中患者,抗血小板治疗比例为58.4%,降压药、降糖药和他汀类药治疗比例分别为82.3%、85.3%和14.2%。年龄≥60岁(P=0.011)、退休(P=0.021)、脑卒中史(P<0.001)、心绞痛史(P=0.001)、心梗史(P=0.037)及高血压史(P=0.016),是抗血小板依从性的促进因素。结论复发性卒中二级预防现状不容乐观,药物干预危险因素治疗依从性低。
Objective To investigate the secondary prevention of ischemic stroke drug treatment compliance and impact of anti-platelet drug compliance factors.Methods From August 2007 to September 2007,ischemic stroke or TIA patients who were admitted into internal medicine of neurology wards of 21 Hospitals in Beijing,a total of 541 recurrent stroke patients who were analyzed,retrospectively.Results There were 541 recurrent stroke patients.Uses of antiplatelet,antihypertension,antidiabetic and lipid-lowering therapy 58.4%,82.3%、85.3% and 14.2%,respectively.Age≥60（P=0.011）,retirement （P=0.021）,history of stroke （P0.001）,history of angina （P=0.001）,history of myocardial infarction （P=0.037） and history of hypertension（P=0.016）was associated with anti-platelet drug compliance.Conclusions The present investigation has revealed a low drug compliance for secondary prevention of ischemic stroke,suggesting that the current status of secondary prevention of recurrent stroke is far from ideal.
出处
《中国神经精神疾病杂志》
CAS
CSCD
北大核心
2010年第10期594-597,共4页
Chinese Journal of Nervous and Mental Diseases
基金
首都医学发展科研基金联合攻关项目(编号:2005-1003)
关键词
缺血性卒中
二级预防
抗血小板
高血压
Ischemic Stroke Secondary Prevention Antiplatelet Hypertension
